Global Cell Therapy Technologies Market

Cell Therapy Technologies Market Size, Share, Growth Analysis, By Technology(Viral Vector Technology, Genome Editing Technology, Somatic Cell Technology, Cell Immortalization Technology), By Use(Clinical Use), By Cell(Stem Cell Therapies, BM, Blood, & Umbilical Cord-derived Stem Cells), By Therapy(Allogenic Therapies, Autologous Therapies), By Product(Consumables, Equipment, Systems, and Software), By Therapeutic Area(Oncology, Musculoskeletal Diseases), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35A2873 | Region: Global | Published Date: April, 2024
Pages: 201 | Tables: 175 | Figures: 74

Cell Therapy Technologies Market News

  • In March 2023, Danaher Corporation began a strategic collaboration with the University of Pennsylvania to address operational challenges affecting the use of cellular immunotherapy.
  • In June 2023, Vertex Pharmaceuticals Incorporated and Lonza disclosed a joint venture to facilitate the creation of Vertex research stem cell therapeutic divisions This treatment is designed to help individuals with type 1 diabetes (T1D), a VX-880 and VX currently undergoing clinical trials Special include focus on systems –264.
  • On October 2023, Nkarta, Inc. (NASDAQ: NKRT) reported a $1.5 billion growth. announced FDA approval of an IND application for evaluation of NKX019 as a candidate for allogeneic, CD19-directed CAR NK cell therapy for lupus nephritis.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cell Therapy Technologies Market size was valued at USD 9.73 Billion in 2022 and is poised to grow from USD 2.12 Billion in 2023 to USD 55.32 Billion by 2031, growing at a CAGR of 12.14% in the forecast period (2024-2031).

The competitive environment of the Cell Therapy Technologies Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Emerging biotechnology companies and start-up companies are leveraging technological innovation and collaborative research to gain competitive advantage and participate in the development of new cell therapies loudly. Partnerships, licensing agreements, and acquisitions are common strategies among market players to expand their capabilities, acquire complementary technologies, and strengthen their market positions. 'Thermo Fisher Scientific Inc.', 'GE Healthcare', 'Lonza Group', 'Merck KGaA (MilliporeSigma)', 'Terumo BCT (Terumo Corporation)', 'STEMCELL Technologies Inc.', 'Sartorius AG', 'Therakos Inc. (Mallinckrodt Pharmaceuticals)', 'Miltenyi Biotec', 'Fresenius Kabi AG', 'Pluristem Therapeutics Inc.', 'MaxCyte Inc.', 'CellGenix GmbH', 'Novartis International AG', 'Gilead Sciences Inc.'

The market growth is also supported by the constant introduction of new technologies to enable cutting-edge therapies. The introduction of proprietary cells is generally considered to be the most efficient way to obtain a large population of targets for a single product. For example, Immunicum is using Chimeric Antigen Receptor T cell (CAR-T) growth, dendritic cell neoantigen presentation technology, and T-cell primers to improve its immuno-oncology product development.

The demand for advanced cell therapy technology is increasing as advanced analytical tools are used for quality control and quality improvement. Combining new diagnostics, imaging technologies and data analytics makes it easy to monitor and characterize cellular materials to ensure efficacy and increased safety profiles. If the focus is on developing new biomaterials and scaffolds to enhance cell delivery and engraftment increases the interest in cell therapy technologies. These properties provide improved biocompatibility, controlled release kinetics, and better retention at the target site, further enhancing the therapeutic potential of cell-based therapies in regulatory development and collaboration involvement and increased collaboration between research institutions supports innovation and accelerates the translation of cell therapy technologies from bench to bedside.

North America accounted for the largest revenue share of 58.7% in 2023. This is due to collaboration between research institutes and major pharmaceutical companies. Growth is coming through several joint ventures in this area. For example, in June 2022, Ematics partnered with Bristol Myers Squibb to develop the Gamma Delta Allogenic Cell Therapy Programs. The United States is a leading player in the cell therapy technology market. It emphasizes the research, development, and development of cell therapies, particularly in cancer, cardiology, and neuroscience in the US. The regulatory environment is supportive of new cell therapies, and the country has a variety of services and research institutes.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Cell Therapy Market
Buy Now GET FREE SAMPLE
T-cell Therapy Market
Buy Now GET FREE SAMPLE
Stem Cell Therapy Market
Buy Now GET FREE SAMPLE
Cancer Biological Therapy Market
Buy Now GET FREE SAMPLE
Cell-Based Assays Market
Buy Now GET FREE SAMPLE
Cell Culture Media Market
Buy Now GET FREE SAMPLE
Cancer Therapeutics Market
Buy Now GET FREE SAMPLE
3D Cell Culture Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Cell Therapy Technologies Market

Report ID: SQMIG35A2873

$5,300
BUY NOW GET FREE SAMPLE